Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Immune-Onc Therapeutics Announces First Patient Dosed with IO-108 in a Randomized Global Phase 1b/2 Study of First-Line Treatment of Advanced Liver Cancer in Clinical Collaboration with Roche
Friday, February 28, 2025ImmuneOnc Therapeutics Inca private clinicalstage biopharmaceutical company advancing novel therapies in immunology and oncology by targeting myeloid cell inhibitory receptors today announced that the first patient has been dosed with IO in a global...
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
Friday, February 28, 2025MAIA Biotechnology Inc a clinicalstage biopharmaceutical company developing targeted immunotherapies for cancer today announced plans to initiate a Phase pivotal trial in named THIO to evaluate the efficacy of THIO administered in sequence
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
Thursday, February 27, 2025MAIA Biotechnology Inc a clinicalstage biopharmaceutical company developing targeted immunotherapies for cancer today announced the trial design for the expansion of its THIO pivotal Phase trial in nonsmall cell lung cancer NSCLC
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
Thursday, February 27, 2025Plus Therapeutics Inc a clinicalstage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system CNS cancers today announced the completion of the ReSPECTLM Phase singledose escalation...
Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline
Wednesday, February 26, 2025Ryvu Therapeuticsa clinicalstage drug discovery and development company focusing on novel oncology therapies that address emerging targets in oncology announced a strategic reorganization that will extend Ryvus cash runway to H to focus on driving t...
LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer
Wednesday, February 26, 2025LIXTE Biotechnology Holdings Inc a clinical stage pharmaceutical company today announced it has added the Robert H Lurie Comprehensive Cancer Center Lurie Cancer Center of Northwestern University as a second site in a clinical trial combining the Com...
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
Tuesday, February 25, 2025Gilead Sciences Inctoday announced that the European Medicines Agency EMA has validated for parallel accelerated review the companys Marketing Authorization Application MAA and EUMedicines for all EUMall application for lenacapavirthe companys twicey...
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
Tuesday, February 25, 2025Nektar Therapeuticsand TrialNet an international clinical trial network at the forefront of diabetes research today announced a new collaboration agreement to evaluate Nektars rezpegaldesleukin in patients with new onset stage type diabetes mellitu...
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Monday, February 24, 2025Sandoz the global leader in generic and biosimilar medicines announces the launch of Pyzchiva ustekinumabttwe in the US From today the medicine is commercially available to patients across the US
CDMO Live Debuts as BioPharma Manufacturing Sector Approaches $200 Billion
Monday, February 24, 2025CDMO Live has emerged as the definitive industry gathering bringing together Europes leading pharmaceutical outsourcing decisionmakers at Rotterdams World Trade Center this May putting the spotlight on this critical sector
